{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:44:56Z","timestamp":1790732696961,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.bbagen.2013.05.005","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T23:00:59Z","timestamp":1368140459000},"page":"5435-5443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":420,"title":["Albumin\u2013drug interaction and its clinical implication"],"prefix":"10.1016","volume":"1830","author":[{"given":"Keishi","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Tuan Giam","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2013.05.005_bb0005","series-title":"All About Albumin: Biochemistry, Genetics, and Medical Applications","author":"Peters","year":"1996"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1248\/bpb.25.695","article-title":"Practical aspects of the ligand-binding and enzymatic properties of human serum albumin","volume":"25","author":"Kragh-Hansen","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0020","doi-asserted-by":"crossref","first-page":"17958","DOI":"10.1073\/pnas.0506440102","article-title":"Locating high-affinity fatty acid-binding sites on albumin by X-ray crystallography and NMR spectroscopy","volume":"102","author":"Simard","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2133\/dmpk.20.309","article-title":"A molecular functional study on the interactions of drugs with plasma proteins","volume":"20","author":"Otagiri","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural basis of the drug-binding specificity of human serum albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0035","series-title":"Clinical Pharmacokinetics and Pharmacodynamics \u2014 Concepts and Applications","author":"Rowland","year":"2010"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJM197602052940605","article-title":"Binding of drugs to serum albumin (first of two parts)","volume":"294","author":"Koch-Weser","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jps.2600660402","article-title":"Binding of drugs by albumin and plasma protein","volume":"66","author":"Vallner","year":"1977","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/jps.2600570601","article-title":"The binding of drugs by plasma proteins","volume":"57","author":"Meyer","year":"1968","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/03602537608995839","article-title":"Plasma and tissue protein binding of drugs in pharmacokinetics","volume":"5","author":"Jusko","year":"1976","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2133\/dmpk.24.342","article-title":"Lessons from the crystallographic analysis of small molecule binding to human serum albumin","volume":"24","author":"Curry","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0065-3233(08)60640-3","article-title":"Structure of serum albumin","volume":"45","author":"Carter","year":"1994","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0075","series-title":"Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring","first-page":"82","article-title":"Influence of protein binding and use of unbound (free) drug concentrations","author":"MacKichan","year":"2005"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0080","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/1869","article-title":"Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites","volume":"5","author":"Curry","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/protein\/12.6.439","article-title":"Crystal structure of human serum albumin at 2.5A resolution","volume":"12","author":"Sugio","year":"1999","journal-title":"Protein Eng."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0090","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0026-895X(25)10691-3","article-title":"The characterization of two specific drug binding sites on human serum albumin","volume":"11","author":"Sudlow","year":"1975","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0095","first-page":"1052","article-title":"Further characterization of specific drug binding sites on human serum albumin","volume":"12","author":"Sudlow","year":"1976","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0100","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1016\/0006-2952(88)90072-X","article-title":"Location and characterization of the warfarin binding site of human serum albumin \u2014 a comparative study of two large fragments","volume":"37","author":"Bos","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0167-4838(88)90007-6","article-title":"Drug-binding and other physicochemical properties of a large tryptic and a large peptic fragment of human serum albumin","volume":"953","author":"Bos","year":"1988","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0110","series-title":"Human Serum Albumin \u2014 New Insights on its Structural Dynamics, Functional Impacts and Pharmaceutical Applications","first-page":"1","article-title":"X-ray crystallography of albumin","author":"Curry","year":"2011"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00498574","article-title":"Azapropazone binding to human serum albumin","volume":"313","author":"Fehske","year":"1980","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0026-895X(25)14614-2","article-title":"Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone","volume":"21","author":"Fehske","year":"1982","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0006-2952(81)90151-9","article-title":"The location of drug binding sites in human serum albumin","volume":"30","author":"Fehske","year":"1981","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0167-4838(96)00013-1","article-title":"Characterization of site I on human serum albumin: concept about the structure of a drug binding site","volume":"1295","author":"Yamasaki","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/bj2090135","article-title":"Relations between high-affinity binding sites for l-tryptophan, diazepam, salicylate and phenol red on human serum albumin","volume":"209","author":"Kragh-Hansen","year":"1983","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1042\/bj2250629","article-title":"Relations between high-affinity binding sites of markers for binding regions on human serum albumin","volume":"225","author":"Kragh-Hansen","year":"1985","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0145","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0026-895X(25)09363-0","article-title":"Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands","volume":"34","author":"Kragh-Hansen","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0150","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/jps.20203","article-title":"Characterization of site I of human serum albumin using spectroscopic analyses: locational relations between regions Ib and Ic of site I","volume":"93","author":"Yamasaki","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jsb.2007.12.004","article-title":"A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography","volume":"162","author":"Zhu","year":"2008","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0160","doi-asserted-by":"crossref","first-page":"22804","DOI":"10.1074\/jbc.M100575200","article-title":"Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I","volume":"276","author":"Petitpas","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0165","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0026-895X(25)14450-7","article-title":"Structural requirements for drug binding to site II on human serum albumin","volume":"24","author":"Wanwimolruk","year":"1983","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0170","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/(SICI)1520-636X(1997)9:7<643::AID-CHIR1>3.0.CO;2-8","article-title":"Stereoselectivity and enantiomer\u2013enantiomer interactions in the binding of ibuprofen to human serum albumin","volume":"9","author":"Itoh","year":"1997","journal-title":"Chirality"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0175","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0167-4838(01)00151-0","article-title":"Flunitrazepam, a 7-nitro-1,4-benzodiazepine that is unable to bind to the indole-benzodiazepine site of human serum albumin","volume":"1546","author":"Chuang","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1472-6807-11-18","article-title":"Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin","volume":"11","author":"Ryan","year":"2011","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0185","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","article-title":"Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin","volume":"303","author":"Bhattacharya","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0190","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0026-895X(25)13820-0","article-title":"Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles","volume":"16","author":"Sj\u00f6holm","year":"1979","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0195","doi-asserted-by":"crossref","first-page":"38731","DOI":"10.1074\/jbc.M005460200","article-title":"Binding of the general anesthetics propofol and halothane to human serum albumin. High resolution crystal structures","volume":"275","author":"Bhattacharya","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jmb.2008.06.016","article-title":"Crystallographic analysis of human serum albumin complexed with 4Z, 15E-bilirubin-IX\u03b1","volume":"381","author":"Zunszain","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0205","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jsb.2010.03.014","article-title":"Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin","volume":"171","author":"Hein","year":"2010","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0210","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.bjp.0707251","article-title":"Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties","volume":"151","author":"Oettl","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0215","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1023\/A:1016057513490","article-title":"Covalent binding between bucillamine derivatives and human serum albumin","volume":"13","author":"Narazaki","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1155\/MBD.1994.527","article-title":"Gold-induced structural switch of cys34 in albumin: comparison of auranofin with aurothiomalate","volume":"1","author":"Christodoulou","year":"1994","journal-title":"Metal-Based Drugs"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0225","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0006-2952(93)90671-I","article-title":"Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin","volume":"46","author":"Keire","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0230","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1021\/js960234+","article-title":"Kinetic analysis of the covalent binding of captopril to human serum albumin","volume":"86","author":"Narazaki","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0731-7085(98)00163-0","article-title":"Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties","volume":"18","author":"Bertucci","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0240","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1074\/jbc.273.24.14721","article-title":"Cisplatin binding sites on human albumin","volume":"273","author":"Ivanov","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00204-001-0318-2","article-title":"Covalent binding of nitrogen mustards to the cysteine-34 residue in human serum albumin","volume":"76","author":"Noort","year":"2002","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0250","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1124\/dmd.106.014233","article-title":"Liquid chromatography\/tandem mass spectrometry detection of covalent binding of acetaminophen to human serum albumin","volume":"35","author":"Damsten","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0255","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0090-9556(25)07118-1","article-title":"The pharmacokinetics of albumin conjugates of d-penicillamine in humans","volume":"19","author":"Joyce","year":"1991","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0260","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1012006306915","article-title":"Covalent binding of a bucillamine derivative with albumin in sera from healthy subjects and patients with various diseases","volume":"14","author":"Narazaki","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0265","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.2042-7158.1986.tb03386.x","article-title":"On the binding of cinmetacin and indomethacin to human serum albumin","volume":"38","author":"Montero","year":"1986","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0270","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1124\/dmd.104.002782","article-title":"Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome","volume":"33","author":"Takamura","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0275","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1749-6632.1973.tb20490.x","article-title":"Drug-protein binding. IV. Modulation of binding Increasing activity of sulfonamides with displacing agents: a review","volume":"226","author":"Anton","year":"1973","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0280","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0006-2952(80)90378-0","article-title":"Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic","volume":"29","author":"Verbeeck","year":"1980","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0285","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0167-4838(99)00174-0","article-title":"Helix 6 of subdomain III A of human serum albumin is the region primarily photolabeled by ketoprofen, an arylpropionic acid NSAID containing a benzophenone moiety","volume":"1434","author":"Chuang","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0290","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0026-895X(25)15032-3","article-title":"Albumin binding of anti-inflammatory drugs Utility of a site-oriented versus a stoichiometric analysis","volume":"25","author":"Honor\u00e9","year":"1984","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0295","article-title":"A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis","author":"Setoguchi","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0300","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/(SICI)1520-636X(1996)8:3<271::AID-CHIR7>3.0.CO;2-K","article-title":"Albumin binding sites for etodolac enantiomers","volume":"8","author":"Mignot","year":"1996","journal-title":"Chirality"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0305","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0026-895X(25)13439-1","article-title":"Competitive binding of long-chain free fatty acids, octanoate, and chlorophenoxyisobutyrate to albumin","volume":"14","author":"Meisner","year":"1978","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2125.1994.tb04251.x","article-title":"Plasma protein binding displacement interactions-why are they still regarded as clinically important?","volume":"37","author":"Rolan","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0315","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0320","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/jps.21916","article-title":"Significance of protein binding in pharmacokinetics and pharmacodynamics","volume":"99","author":"Schmidt","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0325","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0163-7258(82)90012-2","article-title":"Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites","volume":"17","author":"D'Arcy","year":"1982","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0330","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJM197603042941005","article-title":"Drug therapy. Binding of drugs to serum albumin (second of two parts)","volume":"294","author":"Koch-Weser","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0335","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.1964.03060290124046","article-title":"Potentiation of anticoagulants caused by pyrazole compounds","volume":"188","author":"Fox","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0340","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM196703022760904","article-title":"Potentiation of anticoagulant effect of warfarin by phenylbutazone","volume":"276","author":"Aggeler","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0345","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199630060-00002","article-title":"Clinically important drug interactions with anticoagulants. An update","volume":"30","author":"Harder","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0350","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1536\/ihj.51.399","article-title":"Risks and benefits of combined use of bucolome and warfarin in anticoagulation therapy","volume":"51","author":"Hatakeyama","year":"2010","journal-title":"Int. Heart J."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0355","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijpharm.2004.12.009","article-title":"Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions","volume":"293","author":"Osawa","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0360","first-page":"946","article-title":"Displacement of one drug by another from carrier or receptor sites","volume":"58","author":"Brodie","year":"1965","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00561795","article-title":"Effect of phenylbutazone on the binding of vitamin K antagonists to albumin","volume":"6","author":"Tillement","year":"1973","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0370","first-page":"293","article-title":"Evaluation of co-administration of bucolome for warfarin therapy from the view point of protein binding","volume":"12","author":"Abe","year":"1995","journal-title":"Jpn. J. Ther. Drug Monit."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0375","first-page":"505","article-title":"Thrombosis therapy","volume":"15","author":"Matsuoka","year":"1977","journal-title":"Geriatr. Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0380","first-page":"95","article-title":"A new method of anticoagulant therapy used by combination warfarin and bucolome","volume":"88","author":"Majima","year":"1982","journal-title":"Niigata Igaku Kai Zasshi"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0385","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0390","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0090-9556(24)15043-X","article-title":"Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of in vitro approaches to predicting In vivo reduction of (S)-warfarin clearance","volume":"27","author":"Takahashi","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0395","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cpt1977225part1573","article-title":"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole","volume":"22","author":"Pond","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0400","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0090-9556(24)15066-0","article-title":"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments","volume":"28","author":"Komatsu","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0405","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2133\/dmpk.DMPK-10-RG-009","article-title":"Effects of CYP2C9*3 and CYP2C9*13 on diclofenac metabolism and inhibition-based drug-drug interactions","volume":"25","author":"Zi","year":"2010","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1211\/jpp.60.1.0002","article-title":"Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats","volume":"60","author":"Ogata","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0415","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2967\/jnumed.108.060095","article-title":"Competitive displacement of serum protein binding of radiopharmaceuticals with amino acid infusion investigated with N-isopropyl-p-123I-iodoamphetamine","volume":"50","author":"Kuga","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2012.12.002","article-title":"Pharmacokinetic alteration of (99m)Tc-MAG3 using serum protein binding displacement method","author":"Nishi","year":"2013","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0425","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003088-197601010-00003","article-title":"Drug protein binding and the nephrotic syndrome","volume":"1","author":"Gugler","year":"1976","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl. 1","key":"10.1016\/j.bbagen.2013.05.005_bb0430","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2165\/00003088-198400091-00003","article-title":"Alteration of drug-protein binding in renal disease","volume":"9","author":"Reidenberg","year":"1984","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0435","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00007691-199812000-00013","article-title":"Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin","volume":"20","author":"Dasgupta","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0440","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/clpt.1980.87","article-title":"Plasma protein carbamylation and decreased acidic drug protein binding in uremia","volume":"27","author":"Erill","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0445","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000137603","article-title":"Effects of carbamylation of plasma proteins and competitive displacers on drug binding in uremia","volume":"24","author":"Calvo","year":"1982","journal-title":"Pharmacology"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0450","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0022-3565(25)20664-4","article-title":"Mechanism of stereoselective serum binding of ketoprofen after hemodialysis","volume":"278","author":"Sakai","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0455","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/jps.22592","article-title":"Update on the pharmacokinetics and redox properties of protein-bound uremic toxins","volume":"100","author":"Watanabe","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0460","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1248\/bpb.18.1755","article-title":"Characterization of binding site of uremic toxins on human serum albumin","volume":"18","author":"Sakai","year":"1995","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0465","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/clinchem\/43.12.2274","article-title":"Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia","volume":"43","author":"Takamura","year":"1997","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0470","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2005.07.035","article-title":"The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst","volume":"334","author":"Mera","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0475","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/0148607191015004476","article-title":"The role of albumin in human physiology and pathophysiology, Part III: albumin and disease states","volume":"15","author":"Doweiko","year":"1991","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0480","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1528-1157.1997.tb01734.x","article-title":"Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function","volume":"38","author":"Lau","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0485","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1016\/0006-2952(78)90049-7","article-title":"Differentiated effects of liver cirrhosis on the albumin binding sites for diazepam, salicylic acid and warfarin","volume":"27","author":"Kober","year":"1978","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0490","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/lt.21504","article-title":"Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis","volume":"14","author":"Klammt","year":"2008","journal-title":"Liver Transpl."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0495","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/clpt.1984.241","article-title":"Abnormal serum protein binding of acidic drugs in diabetes mellitus","volume":"36","author":"Ruiz-Cabello","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0500","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.biochi.2012.05.017","article-title":"Impaired drug-binding capacities of in vitro and in vivo glycated albumin","volume":"94","author":"Baraka-Vidot","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0505","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1994.tb04304.x","article-title":"Decreased plasma protein binding of valproate in patients with acute head trauma","volume":"37","author":"Anderson","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0510","first-page":"449","article-title":"Protein binding of itraconazole and fluconazole in patients with cancer","volume":"33","author":"Arredondo","year":"1995","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0515","series-title":"Applied Therapeutics: The Clinical Use of Drugs","first-page":"2-1","article-title":"Clinical pharmacokinetics","author":"Winter","year":"1998"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0520","series-title":"Basic Clinical Pharmacokinetics","author":"Winter","year":"2004"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0525","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1665-2681(19)31602-3","article-title":"Extracorporeal liver support-albumin dialysis with the molecular adsorbent recirculating system","volume":"10","author":"Mitzner","year":"2011","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0530","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/039139880803100511","article-title":"Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case","volume":"31","author":"Karvellas","year":"2008","journal-title":"Int. J. Artif. Organs"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0535","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/cc2895","article-title":"Equipment review: the molecular adsorbents recirculating system (MARS)","volume":"8","author":"Boyle","year":"2004","journal-title":"Crit. Care"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0540","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1681\/ASN.V12suppl_1s75","article-title":"Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure","volume":"12","author":"Mitzner","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0545","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1744-9987.2009.00760.x","article-title":"Albumin dialysis in liver failure: comparison of molecular adsorbent recirculating system and single pass albumin dialysis \u2014 a retrospective analysis","volume":"13","author":"Kortgen","year":"2009","journal-title":"Ther. Apher."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0550","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/cc4985","article-title":"Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure","volume":"10","author":"Laleman","year":"2006","journal-title":"Crit. Care"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0555","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/lt.20236","article-title":"Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study","volume":"10","author":"Sen","year":"2004","journal-title":"Liver Transpl."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0560","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1525-1594.1999.06122.x","article-title":"Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support","volume":"23","author":"Stange","year":"1999","journal-title":"Artif. Organs"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0565","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1478-3231.2011.02588.x","article-title":"Clearing of toxic substances: are there differences between the available liver support devices?","volume":"31","author":"Krisper","year":"2011","journal-title":"Liver Int."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0570","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1744-9987.2006.00351.x","article-title":"Albumin regeneration in liver support-comparison of different methods","volume":"10","author":"Mitzner","year":"2006","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0575","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1744-9987.2006.00353.x","article-title":"How can liver toxins be removed? Filtration and adsorption with the Prometheus system","volume":"10","author":"Vienken","year":"2006","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0580","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/cc5922","article-title":"Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure","volume":"11","author":"Karvellas","year":"2007","journal-title":"Crit. Care"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0585","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.ajkd.2004.09.016","article-title":"Phenytoin intoxication in critically ill patients","volume":"45","author":"De Schoenmakere","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0590","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ndt\/gfl640","article-title":"Treatment of severe theophylline poisoning with the molecular adsorbent recirculating system (MARS)","volume":"22","author":"Korsheed","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0595","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1528-1157.2003.31402.x","article-title":"Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS)","volume":"44","author":"Sen","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0600","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/MCC.0b013e3282f0febd","article-title":"Extracorporeal treatment of intoxications","volume":"13","author":"de Pont","year":"2007","journal-title":"Curr. Opin. Crit. Care"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0605","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/15563650500516041","article-title":"Albumin dialysis: a new therapeutic alternative for severe diltiazem intoxication","volume":"44","author":"Pichon","year":"2006","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0610","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.annemergmed.2011.07.029","article-title":"Extracorporeal albumin dialysis in three cases of acute calcium channel blocker poisoning with life-threatening refractory cardiogenic shock","volume":"59","author":"Pichon","year":"2012","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0615","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0272-6386(00)70345-3","article-title":"Charcoal hemoperfusion in the treatment of phenytoin overdose","volume":"35","author":"Kawasaki","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bbagen.2013.05.005_bb0620","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1081\/CLT-50426","article-title":"How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases?","volume":"43","author":"Kawasaki","year":"2005","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.bbagen.2013.05.005_bb0625","first-page":"1","article-title":"Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment","author":"Minomo","year":"2013","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416513002018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416513002018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:26:03Z","timestamp":1745990763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416513002018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":125,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0304416513002018"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2013.05.005","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin\u2013drug interaction and its clinical implication","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2013.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}